Related Experiment Video
Updated: May 12, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
p53 interferes with microtubule-stabilizing agent-induced apoptosis in prostate and colorectal cancer cells
Ji Young Kim1, Jin-Yong Chung, Seung Gee Lee
1Department of Anatomy and Cell Biology, Dong-A University, Busan, Republic of Korea.
Abstract:
Taxanes are microtubule-stabilizing agents that have anticancer activity against several types of human solid tumors. Although the primary mechanism of action of these drugs is well understood, the signaling pathways that confer resistance to these agents in certain types of cancer remain poorly understood. In particular, the association of p53 with the mechanism(s) of taxane-mediated cell death is still controversial. In this study, we showed that p53 has a profound inhibitory effect on docetaxel (Doc)-induced apoptosis in prostate and colorectal cancer cells and that caspases play a critical role in this process. Doc induced prostate cancer cell apoptosis at high levels in p53-null PC3 cells, at intermediate levels in p53-mutant DU145 cells and at low levels in p53 wild-type LNCaP cells. While transient overexpression of p53 in PC3 cells suppressed Doc-induced apoptosis, knockdown of p53 in LNCaP cells increased apoptosis. This finding was further confirmed using an isogenic pair of colorectal cancer cell lines, HCT-116 p53-/- and p53+/+, indicating that p53 inhibits induction of apoptosis by Doc. To our knowledge, this is the first report describing that chemical or genetic knockout of p53 enhances the susceptibility of both prostate and colorectal cancer cells to Doc-induced apoptosis. These results may suggest an approach to stratify patients for regimens involving Doc.
Insights
The tumor suppressor protein p53 inhibits docetaxel-induced apoptosis in prostate and colorectal cancers. Removing p53 enhances cancer cell sensitivity to this chemotherapy, suggesting new patient stratification strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Taxanes are crucial chemotherapy agents targeting microtubules in solid tumors.
- The role of p53 in taxane resistance and cancer cell death remains unclear.
- Understanding p53's influence is vital for optimizing taxane-based therapies.
Purpose of the Study:
- To investigate the role of p53 in docetaxel-induced apoptosis in prostate and colorectal cancer cells.
- To elucidate the signaling pathways, including caspases, involved in p53-mediated taxane resistance.
- To determine if p53 status can predict patient response to docetaxel.
Main Methods:
- Utilized p53-null, p53-mutant, and p53 wild-type prostate cancer cell lines (PC3, DU145, LNCaP).
- Employed an isogenic pair of colorectal cancer cell lines (HCT-116 p53-/- and p53+/+).
- Manipulated p53 levels through transient overexpression and gene knockdown.
- Assessed docetaxel-induced apoptosis and caspase activity.
Main Results:
- p53 significantly inhibited docetaxel-induced apoptosis in both prostate and colorectal cancer cells.
- Apoptosis levels correlated inversely with p53 status: high in p53-null, intermediate in p53-mutant, and low in p53 wild-type cells.
- Overexpression of p53 suppressed apoptosis, while p53 knockdown enhanced it.
- Caspase activity was identified as a critical component in this p53-mediated process.
Conclusions:
- p53 acts as a potent inhibitor of docetaxel-induced apoptosis in prostate and colorectal cancers.
- Genetic or chemical knockout of p53 increases cancer cell sensitivity to docetaxel.
- These findings suggest p53 status as a potential biomarker for stratifying patients for docetaxel-based chemotherapy regimens.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules

